Breaking: Novo, Lilly near deal for cheaper weight loss drugs with Trump administration

The agreement may include an expansion of Medicare and Medicaid coverage for Wegovy and Zepbound.

Log In    Subscribe BREAKING NEWS   Trump administration nears deals for cheaper weight-loss drugs with Novo Nordisk, Eli Lilly By Daniel Payne, Elaine Chen, and Chelsea Cirruzzo Adobe The Trump administration is nearing a deal with Eli Lilly and Novo Nordisk to lower the prices of their weight loss drugs and expand access to them, people familiar with the talks told STAT.   The companies have been close to a deal for weeks, one lobbyist with knowledge of the negotiations said, echoing others who said they believe the parties are closing in on an agreement. The deals have not yet been announced, and the details could still change. READ MORE Sign up for D.C. Diagnosis Washington never stops. Cut through the noise with our essential updates on health care politics and policy. Learn more. In Case You Missed It Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates By Elaine Chen Experts worry FDA's credibility is being shredded by scandal and 'soap opera' By Matthew Herper and Lizzy Lawrence Microdosing aims to extend the lifespan of the GLP-1 compounding market By Katie Palmer Will the White House drug-pricing deal lower costs for Americans? Experts are skeptical By Elaine Chen Don't miss out on another STAT investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us